--- title: Building the Future of Medicine | Acclinate description: Better science starts with better representation. Learn why inclusive research teams are essential to building a more equitable future in medicine. image: https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Who-Builds-the-Future-of-Medicine--Why-Representative-Research-Matters.jpg --- [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate-logo.png?width=2000&height=497&name=Acclinate-logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [eDICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [Contract Research Organizations](https://www.acclinate.com/solutions/for-cros) - [Partners](https://www.acclinate.com/solutions/community-partners) - Company - [About Us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [News](https://news.acclinate.com) - Resources - [Resource Library](https://www.acclinate.com/resources) - [Blog](https://blog.acclinate.com) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [Glossary](https://www.acclinate.com/glossary) - [FAQ](https://www.acclinate.com/faq) - [Talk to Our Team](https://info.acclinate.com/get-in-touch) [![Talk to Our Team](https://no-cache.hubspot.com/cta/default/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302.png)](https://cta-redirect.hubspot.com/cta/redirect/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302) [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate_Logo.png?width=500&height=149&name=Acclinate_Logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [**NOWINCLUDED**Acclinate’s B2C community platform ](https://www.acclinate.com/products/nowincluded-the-community) - [**e-DICT**Acclinate’s patented AI-powered technology ](https://www.acclinate.com/products/e-dict) - Solutions - [**Pharmaceutical Companies**Community-driven recruitment and real-world insights to support diverse, compliant clinical trials. ](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [**Contract Research Organization (CRO)**Scalable patient engagement and recruitment solutions that reduce risk and improve enrollment timelines. ](https://www.acclinate.com/solutions/for-cros) - [**Partners**Trusted partnerships that connect research opportunities with the communities they aim to serve. ](https://www.acclinate.com/solutions/community-partners) - Company - [**About us**We help clinical research teams reach diverse communities, build trust, and improve trial participation. ](https://www.acclinate.com/about) - [**Careers**Join a mission-driven team advancing inclusive clinical research and community-powered health innovation. ](https://www.acclinate.com/careers) - Resources - [**Resources Hub** ](https://www.acclinate.com/resources) - [**Glossary** ](https://www.acclinate.com/glossary) - [**Press Kit** ](https://www.acclinate.com/press-kit) - [**Events** ](https://www.acclinate.com/events) - [**Blog** ](https://blog.acclinate.com/) - [**News** ](https://news.acclinate.com/) - [![](https://cdn.prod.website-files.com/695fbca039298e2117988a78/69e7b588548c7ad7bd8ab0bc_9dd915489696393dc63d7785ee2e52c7_Question%20mark%20image.png) **FAQs** ](https://www.acclinate.com/faq) - [ Contact Us ](https://www.acclinate.com/contact-us) Stay up to date Get news directly in your inbox Topic All - [Affective Trust ](https://blog.acclinate.com/tag/affective-trust) - [Announcement ](https://blog.acclinate.com/tag/announcement) - [Clinical Research Software ](https://blog.acclinate.com/tag/clinical-research-software) - [Clinical Trial Recruitment Strategies ](https://blog.acclinate.com/tag/clinical-trial-recruitment-strategies) - [Community ](https://blog.acclinate.com/tag/community) - [Diversity in Clinical Trials ](https://blog.acclinate.com/tag/diversity-in-clinical-trials) - [e-DICT™ ](https://blog.acclinate.com/tag/e-dict) - [FDA Diversity Plan ](https://blog.acclinate.com/tag/fda-diversity-plan) - [FDA Guidance: Diversity in Clinical Trials ](https://blog.acclinate.com/tag/fda-guidance-diversity-in-clinical-trials) - [Health Equity ](https://blog.acclinate.com/tag/health-equity) - [Partnerships ](https://blog.acclinate.com/tag/partnerships) - [Representation in Healthcare ](https://blog.acclinate.com/tag/representation-in-healthcare) [Diversity in Clinical Trials](https://blog.acclinate.com/topic/diversity-in-clinical-trials) # Who Builds the Future of Medicine? Why Representative Research Matters Better science starts with better representation. Learn why inclusive research teams are essential to building a more equitable future in medicine. ![Who Builds the Future of Medicine? Why Representative Research Matters](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Who-Builds-the-Future-of-Medicine--Why-Representative-Research-Matters.jpg) Clinical Trial Diversity: What Does It Really Mean? Clinical trials are critical for evaluating the safety and effectiveness of medical devices and pharmaceutical products. The results of trials guide t... Read More ![ Shayla Wilson, MPH](https://blog.acclinate.com/hubfs/65bd36a1a1e1835c9c046b80_Group%205.png) [Shayla Wilson, MPH](https://blog.acclinate.com/author/shayla-wilson-mph) Head of Community Share this Post: [**](https://www.facebook.com/sharer/sharer.php?u=https://blog.acclinate.com/building-the-future-of-medicine) [**](https://twitter.com/home?status=https://blog.acclinate.com/building-the-future-of-medicine) [** ](https://www.linkedin.com/shareArticle?mini=true&url=https://blog.acclinate.com/building-the-future-of-medicine&title=Building%20the%20Future%20of%20Medicine%20|%20Acclinate) Stay up to date Get news directly in your inbox When we talk about disparities in healthcare, we often focus on patient access—who gets invited to participate in clinical trials or who receives care. But inequity runs deeper than participation. It extends to the people behind the scenes: the scientists, researchers, clinical trial designers, and biotech leaders who shape what medicine looks like in the first place.  [![Download Now – Increasing Diversity in Clinical Trials: A Comprehensive Guide for Pharma Companies](https://no-cache.hubspot.com/cta/default/19943632/interactive-169988622868.png) ](https://blog.acclinate.com/hs/cta/wi/redirect?encryptedPayload=AVxigLJUaXF%2By9DGUL%2FuqAx7hnDjf2UzMKdxwlgfwZlPJ2Lhs8jUsjdLOf27iX%2BBxI8X%2BWGwPPoCdnZhibHrXpyFFzPoGQQojffxFHFjc%2F3SocTGyHIrnNN9KBX5UGcCtgnqgO9bYH%2BDGl6WTqwsqFx2YEEl3M9IT7NN2EBq4ZhV9A1%2F7QubcapTtPTrEhhNXAw9SJ%2F0gs2uSnardzNXcCVGqo4Dam8K33wttF%2FLRg%3D%3D&webInteractiveContentId=169988622868&portalId=19943632) The uncomfortable truth is that the future of medicine has long been built by a narrow slice of the population. In fact, a [comprehensive 2021 study](https://www.appliedclinicaltrialsonline.com/view/improving-diversity-in-clinical-trial-volunteer-participation-by-addressing-racial-and-ethnic-representation-among-the-clinical-research-workforce) revealed only 30% of BIPOC medical and allied health professionals reported being invited into clinical research by a mentor or peer, compared to 42% of their white counterparts, highlighting disparities in access to mentorship and entry into clinical research careers.  When research teams don’t reflect the people they aim to serve, blind spots form—gaps in understanding, empathy, and scientific accuracy. It’s time to admit that representation in research is as much about fairness as it is about outcomes—better science, better ROI, and a healthier future for everyone.  ## When You Don’t See Yourself in Healthcare I’ve worked in community engagement long enough to know that trust is personal. We often hear from community members, especially Black American women, that they only trust their doctor if they happen to find the right one. That search for someone who listens, understands, and believes them can be exhausting. And it stems from a system that isn’t built with us in mind.  This isn’t ancient history. Dismissal and misdiagnosis still happens—daily. Just recently, a community member told me they visited the doctor for persistent back pain and was told to “just stretch more.” She later learned she could be facing a serious autoimmune disorder. These gaps in care aren’t rare. They’re routine. And, ultimately, they point to a deeper equity problem in how medicine is practiced and who shapes its future.  Worse still, these experiences chip away at the willingness to seek care at all. When your pain is ignored, your concerns are minimized, or your background is used to make assumptions, it’s no wonder that trust breaks down. But this erosion of confidence is not just a social issue—it becomes a public health crisis when entire communities disengage from preventive care, clinical trials, or emerging therapies.  ## Health Equity Blind Spots in Research Design  Bias doesn’t start in the clinic. It extends throughout the healthcare ecosystem, including within the lab.  When research teams lack representation, the studies they design often exclude entire groups of people. Pregnant women. Non-English speakers. People with disabilities. And yes, communities of color—who are routinely overlooked or written off before they’re even invited to participate.  That exclusion has consequences. For instance, [pulse oximeters often misread oxygen levels in patients with darker skin](https://apnews.com/article/oximeters-race-skin-blood-oxygen-fda-color-d5fde9b81251ac9d4e39c11264638909). This isn’t just due to technical glitches—it's the result of biased design developed by non-representative teams. If the data going in is incomplete, the outcomes coming out will be flawed. And in medicine, that can be a matter of life and death.  This pattern repeats across areas like dermatology, pain management, mental health, and even pediatric care. Products, algorithms, and protocols are created with a default “standard” in mind—often White, male, English-speaking, and able-bodied. That exclusionary default leaves too many people out of the equation, platforming a future where some receive quality care and others are left with few options.  ## **Equity in Clinical Research Isn’t Just Moral—It’s Strategic**  Some people still view representation in science solely as a moral initiative. But it’s not just the right thing to do—it’s the smart thing to do.  Take clinical trials. If your inclusion criteria are so strict that they rule out the very people you’re hoping to help, you’ve already limited your impact. In one sarcoidosis study we supported, patients taking commonly prescribed steroids were automatically excluded—despite the fact that steroids are the standard treatment. That design flaw made it nearly impossible to recruit patients with more severe symptoms.   In another case, a vitiligo study was struggling to diversify its participant pool. Instead of relying on the same large academic research sites, we advocated for a community-based research center closer to the study population. The result? More inclusive enrollment and deeper community engagement.  When you bring new voices to the table to reinforce [equity in clinical research](https://www.acclinate.com/how-it-works), you’re not slowing science down—you’re accelerating its relevance and reach. True innovation isn’t just about moving fast. It’s about moving forward together. **Need to jumpstart your health equity initiative? [Read our 3-step guide to engaging communities of color—responsibly, genuinely, and for the long term](https://info.acclinate.com/3-steps-to-engage-communities-of-color). ** ## **Trial Representation Improves the Bottom Line**  Let’s talk numbers. The cost of exclusion is concretely financial.  Every time a treatment is misapplied, a diagnosis is incorrect, or a patient disengages from the system due to mistrust—that’s money lost. More importantly, that’s a life impacted. The healthcare industry spends billions correcting avoidable errors, developing drugs that don’t work for enough people, and launching campaigns to rebuild fractured confidence.  Now imagine what we could save by getting it right from the beginning. Trials that actively include investigators and researchers from different backgrounds. Outreach based in [Affective Trust](https://blog.acclinate.com/why-affective-trust-is-essential-to-value-based-care), not churn-and-burn tactics. Teams that listen, not just dictate.  In such a scenario, representation becomes a return on investment. When more people can safely and effectively use a product, you’re expanding your market. When your treatments are informed by a full spectrum of potential patients, you’re minimizing risk, not introducing it.  This is about smarter science, stronger engagement, and sustainable growth. And companies that catch on early will be poised not only to develop better medicine, but to also realize better profits.  ## **So, Who Should Build the Future of Medicine?**  It’s simple. The people who will live in that future.  Medicine can’t serve a changing world with yesterday’s mindset. The future of medicine must reflect the full spectrum of people it’s meant to help—across race, gender, age, income, geography, and lived experience.  Only by including perspectives that have long been ignored can we unleash the full potential of science. And that hinges on empowering a new generation of researchers, practitioners, and community leaders who are as representative as the patients they serve.  At Acclinate, we’ve seen what happens when you center communities in the conversation. [You build trust](https://acclinate-marketing-site-f2950ccfeaf088.webflow.io/achieving-affective-trust-actionable-insights-into-advancing-health-equity). You uncover blind spots. You get better results. That means moving beyond recruitment tactics to genuine, long-term strategies that set the foundation for sustainable improvement.  Because when everyone is at the table, the future of medicine gets better for all people.  Ready to learn how Acclinate can help you? [Contact us for a consultation](https://info.acclinate.com/get-in-touch).  [![Increasing Diversity in Clinical Trials](https://no-cache.hubspot.com/cta/default/19943632/interactive-170609956904.png) ](https://blog.acclinate.com/hs/cta/wi/redirect?encryptedPayload=AVxigLLvmHAMLOPOwEeMH2g7eR5%2BzIDdQPseq5E6%2Bv54eBG%2Bjt0eRiB1pspvpVWupFT0MrSU18PHQpqZbXWYb312uQfh98XDjdbDUsx5WSi3WJimWKqIgo410%2BzJDrhXYlwk6rbns%2FkMOeqQmCJ9RmB6h6HC9LkxS%2FcdcPGfKSF%2Boj1yhOMWYrJH4Datw6GqYpK%2BW6OupPl7YYuYlHsWAM6yQiwtWQc2X8LBBtvYDg%3D%3D&webInteractiveContentId=170609956904&portalId=19943632) ## Recent Posts [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [ Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) June 25, 2026 3 Min Read Drug development economics are changing. Sponsors are increasingly relying on a single pivotal trial to support approval. Though the goal of this appr... Read More [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [ Clinical Trial Generalizability: What Regulators Will Scrutinize Next ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) June 25, 2026 3 Min Read For years, generalizability was framed as a methodological concern. Reviewers debated whether results could reasonably extend beyond a trial’s enrolle... Read More [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [ Site Engagement Index (SEI): Measuring What Actually Builds Trust ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) June 25, 2026 3 Min Read Clinical research lacks anything but metrics. Enrollment targets, site activation timelines, and digital engagement rates are tracked closely across s... Read More [![](https://blog.acclinate.com/hubfs/Imported_Blog_Media/6567a9f90c0cf111067913e2_Merck%20Pop%20Up2.png) ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) [ Acclinate to support Merck's oncology clinical trials ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) June 24, 2026 1 Min Read Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to h... Read More [![Why Trial Diversity Is Now a Risk Management Strategy](https://blog.acclinate.com/hubfs/Why-Trial-Diversity-Is-Now-a-Risk-Management-Strategy.jpg) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [ The New Control Lever: Why Trial Diversity Is Now a Risk Management Strategy ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) March 2, 2026 3 Min Read For years, conversations around trial diversity were framed as ethical or reputational concerns. That framing no longer reflects regulatory reality. Read More [![Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity](https://blog.acclinate.com/hubfs/AdobeStock_470269560.webp) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [ Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) February 16, 2026 3 Min Read Clinical research equity efforts originate with good intentions. But they often hit a roadblock in practice: communities are asked to participate in h... Read More [![How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust](https://blog.acclinate.com/hubfs/AdobeStock_1631551849.webp) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [ How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) February 9, 2026 3 Min Read Reaching underrepresented communities in healthcare research has never been simple. Participation decisions are shaped by lived experience, historical... Read More [![Data-Driven Inclusion](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Acclinate-Data-Driven-Inclusion.jpg) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [ Data-Driven Inclusion: Predictive Analytics for Trial Enrollment ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) February 2, 2026 2 Min Read Subpar enrollment remains one of the most common causes of trial delays. But sponsors often miss a key factor: underrepresentation. Lack of diversity ... Read More [![Exploring Diversity in Clinical Research With Acclinate](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Exploring-Diversity-in-Clinical-Research-With-Acclinate.jpg) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [ Exploring Diversity in Clinical Research With Acclinate ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) January 26, 2026 3 Min Read Diversity in clinical research remains a widely discussed goal, yet progress has been uneven. Trials still grapple with subpar representation, limited... Read More [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) June 25, 2026 Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World Read More ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) June 25, 2026 Clinical Trial Generalizability: What Regulators Will Scrutinize Next Read More ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) June 25, 2026 Site Engagement Index (SEI): Measuring What Actually Builds Trust Read More ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) ![Woman wearing Acclinate Shirt](https://blog.acclinate.com/hs-fs/hubfs/layer1_image.webp?width=1600&height=1068&name=layer1_image.webp) ![Medical Research Software e-DICT](https://blog.acclinate.com/hs-fs/hubfs/layer2_image.webp?width=885&height=885&name=layer2_image.webp) ![layer2.2_image](https://blog.acclinate.com/hs-fs/hubfs/layer2.2_image.webp?width=1505&height=1197&name=layer2.2_image.webp) ![layer3_image](https://blog.acclinate.com/hs-fs/hubfs/layer3_image.webp?width=1600&height=1067&name=layer3_image.webp) ## Ready to Measure Your True Impact? Partner with Acclinate to turn mission into measurable, data-driven action. [ Get Started ](https://www.acclinate.com/contact-us) [![Acclinate Logo Reversed](https://blog.acclinate.com/hs-fs/hubfs/footer_logo.png?width=1600&height=398&name=footer_logo.png "Acclinate Logo Reversed")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [e-DICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [CROs](https://www.acclinate.com/solutions/for-cros) - [Community Partners](https://www.acclinate.com/solutions/community-partners) - Resources - [Resources Hub](https://www.acclinate.com/resources) - [Glossary](https://www.acclinate.com/glossary) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [News](https://news.acclinate.com/) - [Blog](https://blog.acclinate.com/) - [FAQs](https://www.acclinate.com/faq) - Company - [About us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [Contact Us](https://www.acclinate.com/contact-us) - Follow Us - [** Linkedin](https://www.linkedin.com/company/acclinateinc/) - [Privacy Policy](https://www.acclinate.com/privacy) - [Terms of Service](https://www.acclinate.com/terms-of-use-acclinate) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Shayla Wilson, MPH", "url" : "https://blog.acclinate.com/author/shayla-wilson-mph" }, "dateModified" : "2026-06-18T19:17:12.151Z", "datePublished" : "2025-04-29T18:56:52.000Z", "headline" : "Building the Future of Medicine | Acclinate", "image" : [ "https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Who-Builds-the-Future-of-Medicine--Why-Representative-Research-Matters.jpg" ], "mainEntityOfPage" : { "@id" : "https://blog.acclinate.com/building-the-future-of-medicine", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.acclinate.com/hubfs/Acclinate-logo.png" }, "name" : "Acclinate" } } ```